R
Rob N. de Jong
Researcher at Genmab
Publications - 60
Citations - 2829
Rob N. de Jong is an academic researcher from Genmab. The author has contributed to research in topics: Antibody & Antigen. The author has an hindex of 24, co-authored 57 publications receiving 2361 citations. Previous affiliations of Rob N. de Jong include Utrecht University & Radboud University Nijmegen.
Papers
More filters
Journal ArticleDOI
Complement is activated by IgG hexamers assembled at the cell surface.
Christoph A. Diebolder,Christoph A. Diebolder,Frank J. Beurskens,Rob N. de Jong,Roman I. Koning,Kristin Strumane,Margaret A. Lindorfer,Marleen Voorhorst,Deniz Ugurlar,Sara Rosati,Albert J. R. Heck,Jan G. J. van de Winkel,Ian A. Wilson,Abraham J. Koster,Ronald P. Taylor,Erica Ollmann Saphire,Dennis R. Burton,Dennis R. Burton,Janine Schuurman,Piet Gros,Paul W. H. I. Parren +20 more
TL;DR: This work found that specific noncovalent interactions between Fc segments of immunoglobulin G (IgG) antibodies resulted in the formation of ordered antibody hexamers after antigen binding on cells, thereby triggering the complement cascade.
Journal ArticleDOI
A comparison of specific leaf area, chemical composition and leaf construction costs of field plants from 15 habitats differing in productivity
Hendrik Poorter,Rob N. de Jong +1 more
TL;DR: SLA in the field was generally lower than in the laboratory, but showed consistency in that the ranking across species remained the same, although individual species sometimes deviated substantially from the general trend.
Journal ArticleDOI
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
Pauline A. van Schouwenburg,Lotte A van de Stadt,Rob N. de Jong,Esther E.L. van Buren,Simone Kruithof,Els R. de Groot,M. Hart,S. Marieke van Ham,Theo Rispens,Lucien A. Aarden,Gerrit Jan Wolbink,Diana Wouters +11 more
TL;DR: The humoral immune response against adalimumab is highly restricted and limited to the idiotype of the therapeutic antibody, thereby providing a mechanism by which AAA formation leads to clinical non-response.
Journal ArticleDOI
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
Rob N. de Jong,Frank J. Beurskens,Sandra Verploegen,Kristin Strumane,Muriel D. van Kampen,Marleen Voorhorst,Wendy Horstman,Patrick J. Engelberts,Simone C. Oostindie,Guanbo Wang,Albert J. R. Heck,Janine Schuurman,Paul W. H. I. Parren,Paul W. H. I. Parren,Paul W. H. I. Parren +14 more
TL;DR: The identified IgG1 Fc backbones provide a novel platform for the generation of therapeutics with enhanced effector functions that only become activated upon binding to target cell–expressed antigen.
Journal ArticleDOI
Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen.
Guanbo Wang,Rob N. de Jong,Ewald T. J. van den Bremer,Frank J. Beurskens,Aran F. Labrijn,Deniz Ugurlar,Piet Gros,Janine Schuurman,Paul W. H. I. Parren,Albert J. R. Heck +9 more
TL;DR: Strikingly, antigen binding by IgG hexamers or deletion of the Fab arms substantially potentiated complement initiation, suggesting that Fab-mediated effects impact downstream Fc-mediated events.